

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

12 January 2011

Exiqon releases second generation human and mouse microRNA inhibitor libraries

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of the 2nd generation of miRCURY LNA™ microRNA Inhibitor libraries for genome-wide screening of microRNA function in human and mouse. Several libraries have already been shipped to the first customers.

The new human microRNA inhibitor library targets almost 1,000 different microRNAs which makes it the library with the highest coverage on the market. The human library also targets 40 proprietary miRPlus™ microRNAs. The new mouse library likewise has the highest coverage as it targets more than 700 microRNAs.

“By use of our proprietary LNA™ technology we have been able to design highly potent microRNA inhibitors with uniform and specific affinity for their targets which is critical for successful high throughput screenings”, said Vice President Sales & Marketing, Dr. Henrik M. Pfundheller and added: “Due to the high potency caused by the high affinity and biostability of the LNA™, the microRNA inhibitors may be applied at very low concentrations minimizing problems with secondary effects”.

Information about the miRCURY LNA™ microRNA Inhibitor products is available at Exiqon’s website: <http://www.exiqon.com/mirna-inhibitor>

Additional information:

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

